ELTROMBOPAGEltrombopag drug may be needed as part of combination therapy. Thereby drug may need to take it with other medications. Eltrombopag is a prescription drug which is used under the guidance of the doctor
INDICATIONEltrombopag is mainly indicated for the treatment of patients having Reduced platelet levels due to chronic immune thrombocytopenia
Eltrombopag is mainly indicated for the treatment of patients having reduced platelet counts due to chronic hepatitis C virus infection Eltrombopag is mainly indicated for the treatment of patients having Severe Aplastic Anemia
1. First line treatment of severe Aplastic Anemia
2. Treatment of refractory severe Aplastic Anemia
MECHANISM OF ACTIONEltrombopag exist in a class of drugs called thrombopoietin (TPO) receptor agonists. Classification of drugs is an association of medications which work in a similar way. These drugs are often used to treat similar conditions.
DOSAGE AND ADMINISTRATIONChronic Hepatitis C-associated Thrombocytopenia:
The recommended dose: 25 mg PO qDay
The dose is Adjust in 25 mg accretion q2weeks PRN to attain target Pelt needed to start/control antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day
Severe Aplastic Anemia
COMMON SIDE EFFECTS• nausea
• pain in head
• decreased appetite
• low red blood cells
PRECAUTIONSIf the patients have cataracts, avoid the drug due to the drug effects cataracts and make the condition worse. Disease progression warning: Avoid using the drug while the patients have myelodysplastic syndrome (MDS), will increase the risk of death. If other blood clot risk factors, then avoid the drug because it will increase platelet counts and blood clots.
DRUG-DRUG INTERACTIONThese drug sezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan interaction with Eltrombopag will increase of side effects. hence the doctor may reduce your dosage of these drugs if required.
PREGNANCYPregnancy category is C
Animal studies reveal risk and human studies not available or neither animal nor human studies done.Use the Eltrombopag with caution if asset outweigh risks
LACTATIONThe drug is not recommended during breastfeeding.
STORAGEStore at room temperature 20°C and 25°C Discard the left-out medicine if not used within 30 minutes.
MISSED DOSEIn the case of the missed dose, patients must consult with the medical practitioner and follow the instructions given by them. thereby missed dose should be avoided and follow the regular dosing schedule.
FOR MORE INFORMATION: